# Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy

> **NCT05847049** · — · COMPLETED · sponsor: **Dar El Oyoun Hospital** · enrollment: 16 (actual)

## Conditions studied

- Central Serous Chorioretinopathy

## Interventions

- **OTHER:** Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy

## Key facts

- **NCT ID:** NCT05847049
- **Lead sponsor:** Dar El Oyoun Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-28
- **Primary completion:** 2023-03-25
- **Final completion:** 2023-04-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05847049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05847049, "Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05847049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*